- In November 2020, Alnylam has announced that the U.S. Food and Drug Administration (FDA) has approved OXLUMO (lumasiran), making it the first and only treatment authorized for Primary Hyperoxaluria Type 1 to reduce urinary oxalate levels in both pediatric and adult patients
Frequently Asked Questions
The market is segmented based on Segmentation, By Drug Class (Miscellaneous Metabolic Agents and Others), Application (Primary Hyperoxaluria and Others), Dosage form (Injection and Solution), Route of Administration (Subcutaneous), Demographic (Adult and Pediatric), End-Users (Clinics, Hospitals, Diagnostic center, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2032
.
The Global Lumasiran Market size was valued at USD 181.95 USD Million in 2024.
The Global Lumasiran Market is projected to grow at a CAGR of 15.4% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
